| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/31/2006 | US20060191375 Methods for fine powder formation |
| 08/31/2006 | DE202006003249U1 Preparation useful for treating wound, comprises natural complex of chitin, 1,3-beta-D-glucan, 1,6-beta-D-glucan and melanin that is produced from fungus of Fomes fomentarius, where component is used for powder basic substance |
| 08/31/2006 | DE102005009217A1 New phosphoric acid salts of 6-dimethylaminomethyl -1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane useful to treat e.g. pain, migraine, depressions, neurodegenerative illnesses, cognitive illnesses, fear conditions and epilepsy |
| 08/31/2006 | DE102005008921A1 Neue Arzneimittel zur Behandlung von Atemwegserkrankungen New drugs for the treatment of respiratory disorders |
| 08/31/2006 | DE102005008183A1 New heterocyclylamide-substituted imidazole compounds useful to treat or prevent viral infections |
| 08/31/2006 | DE102005007468A1 Kovalent gebundene Wirkkomplexe, aus denen Stress-aktivierbare Hautenzyme einen Wirkstoff freisetzen Covalently bound active complexes, from which stress-activated skin enzymes releasing a drug |
| 08/31/2006 | DE102004060314A1 Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen Active ingredient combinations of one or more isoflavonoids and carnitine and / or one or more acyl-carnitines |
| 08/31/2006 | CA2821046A1 An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions |
| 08/31/2006 | CA2805761A1 Nanoparticles of gemcitabine derivatives |
| 08/31/2006 | CA2768075A1 Dosage form containing oxycodone and naloxone |
| 08/31/2006 | CA2752738A1 Small molecule inhibitors of mdm2 and uses thereof |
| 08/31/2006 | CA2683975A1 Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| 08/31/2006 | CA2642927A1 Methods for treatment of retinal degenerative disease |
| 08/31/2006 | CA2633940A1 Preventive or therapeutic agent for cardiac dysfunction or myocardial injury caused by ischemia or ischemia reperfusion |
| 08/31/2006 | CA2614731A1 Multimediator dopamine transport inhibitors, and uses related thereto |
| 08/31/2006 | CA2614223A1 A registry method and control system for dea schedule ii-v medicines |
| 08/31/2006 | CA2609440A1 Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications |
| 08/31/2006 | CA2601935A1 Nk1 antagonists |
| 08/31/2006 | CA2601687A1 Pharmaceutical combination of bcr-abl and raf inhibitors |
| 08/31/2006 | CA2600603A1 Formulations of ladostigil tartrate |
| 08/31/2006 | CA2600046A1 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone |
| 08/31/2006 | CA2600010A1 Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof |
| 08/31/2006 | CA2599454A1 Activator for peroxisome proliferator activating receptor d |
| 08/31/2006 | CA2599449A1 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors |
| 08/31/2006 | CA2599393A1 Small molecule inhibitors of stat3 and the uses thereof |
| 08/31/2006 | CA2599378A1 Tadalafil having a large particle size and a process for preparation thereof |
| 08/31/2006 | CA2599348A1 Indole compound and use thereof |
| 08/31/2006 | CA2599320A1 Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| 08/31/2006 | CA2599315A1 Composition for reducing the exudation of serum proteins |
| 08/31/2006 | CA2599301A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| 08/31/2006 | CA2599295A1 Method of producing proanthocyanidin oligomer |
| 08/31/2006 | CA2599213A1 Dronabinol compositions and methods of using same |
| 08/31/2006 | CA2599212A1 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| 08/31/2006 | CA2599210A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 08/31/2006 | CA2599206A1 Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject |
| 08/31/2006 | CA2599182A1 Regulators of protein misfolding and aggregation and methods of using the same |
| 08/31/2006 | CA2599172A1 Method for the treatment of retinopathy of prematurity and related retinopathic diseases |
| 08/31/2006 | CA2599164A1 Novel pyridine derivatives as potassium ion channel openers |
| 08/31/2006 | CA2599151A1 Novel quinoline derivatives as potassium ion channel openers |
| 08/31/2006 | CA2599150A1 Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197 |
| 08/31/2006 | CA2599124A1 Imidazo (1,2-a) pyridine compounds as vegf-r2 inhibitors |
| 08/31/2006 | CA2599115A1 Novel combinational use of sulfonamide compound |
| 08/31/2006 | CA2599021A1 Novel antithrombotic substituted pyrrolidinones, the production and use thereof in the form of medicaments |
| 08/31/2006 | CA2598995A1 Dimeric iap inhibitors |
| 08/31/2006 | CA2598993A1 Tetrahydroindolone and tetrahydroindazolone derivatives |
| 08/31/2006 | CA2598956A1 Bicyclic heteroaromatic derivatives useful as anticancer agents |
| 08/31/2006 | CA2598943A1 4-0x0quinaz0lin-3-yl benzamide derivatives for the treatment of cytokine diseases |
| 08/31/2006 | CA2598934A1 Pyridyl acetic acid compounds |
| 08/31/2006 | CA2598914A1 Novel drugs for treating respiratory diseases |
| 08/31/2006 | CA2598869A1 Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-prop an-2-ol compounds |
| 08/31/2006 | CA2598853A1 Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists |
| 08/31/2006 | CA2598846A1 Purification process of crude terbinafine from non-metal contaminants |
| 08/31/2006 | CA2598845A1 Phosphate salts of 6-dimethylaminomethyl-l-(3-methoxyphenyl)-1,3-dihydr oxy-cyclohexane compounds |
| 08/31/2006 | CA2598838A1 Multimediator 5-ht6 receptor antagonists, and uses related thereto |
| 08/31/2006 | CA2598831A1 Methods of treating gastrointestinal inflammation |
| 08/31/2006 | CA2598827A1 An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions |
| 08/31/2006 | CA2598759A1 Trofosfamide containing film-coated tablets and procedure for its production |
| 08/31/2006 | CA2598692A1 Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
| 08/31/2006 | CA2598658A1 Hydrophobic starch compositions and uses of starch as fuel |
| 08/31/2006 | CA2598656A1 Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| 08/31/2006 | CA2598651A1 Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| 08/31/2006 | CA2598645A1 Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol |
| 08/31/2006 | CA2598639A1 Hydroxyalkyl substituted imidazonaphthyridines |
| 08/31/2006 | CA2598579A1 Crystalline forms of (1rs,3rs,6rs)-6-dimethvlaminomethvl-1-(3-methoxv- phenyl)cyclohexane-1 ,3-diol hydrochloride |
| 08/31/2006 | CA2598568A1 Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| 08/31/2006 | CA2598531A1 Benzazole potentiators of metabotropic glutamate receptors |
| 08/31/2006 | CA2598525A1 Nerve regeneration promoting agent |
| 08/31/2006 | CA2598517A1 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease |
| 08/31/2006 | CA2598439A1 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| 08/31/2006 | CA2598437A1 Method of preferentially inducing the biosynthesis of interferon |
| 08/31/2006 | CA2598418A1 Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
| 08/31/2006 | CA2598330A1 1-(2h)-isoquinolone derivative |
| 08/31/2006 | CA2598327A1 Ocaperidone salts and pharmaceutical compositions containing the same |
| 08/31/2006 | CA2598279A1 Dosage and method for attaining beneficial levels of vitamin d3 |
| 08/31/2006 | CA2598278A1 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| 08/31/2006 | CA2598210A1 Solid pharmaceutical composition comprising telithromycin |
| 08/31/2006 | CA2598144A1 Compositions and methods for targeted delivery of immune response modifiers |
| 08/31/2006 | CA2598133A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 08/31/2006 | CA2598043A1 Benzisothiazoles useful for treating or preventing hcv infection |
| 08/31/2006 | CA2598031A1 Aqueous topical gel of high stability based on metronidazole and method of preparation |
| 08/31/2006 | CA2598016A1 Amorphous lercanidipine hydrochloride |
| 08/31/2006 | CA2597845A1 Compositions and their uses directed to il-4r alpha |
| 08/31/2006 | CA2597802A1 Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases |
| 08/31/2006 | CA2597781A1 Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof |
| 08/31/2006 | CA2597667A1 Anti-cancer and anti-microbial oxazolidinones and analogues |
| 08/31/2006 | CA2597460A1 Nitric oxide enhancing diuretic compounds, compositions and methods of use |
| 08/31/2006 | CA2597456A1 Inhibitors of akt activity |
| 08/31/2006 | CA2597446A1 Substituted imidazoquinolines and imidazonaphthyridines |
| 08/31/2006 | CA2595295A1 Protease inhibitor precursor synthesis |
| 08/31/2006 | CA2595257A1 Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| 08/31/2006 | CA2594763A1 Clopidogrel base suitable for pharmaceutical formulation and preparation thereof |
| 08/31/2006 | CA2594165A1 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission |
| 08/31/2006 | CA2594127A1 Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
| 08/31/2006 | CA2593750A1 Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
| 08/31/2006 | CA2589479A1 Osmotic device containing amantadine and an osmotic salt |
| 08/31/2006 | CA2586080A1 Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| 08/30/2006 | EP1696028A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/30/2006 | EP1695986A2 Anti-erb B2 antibodies |
| 08/30/2006 | EP1695982A1 Glycosylation-deficient hepatocyte growth factor |
| 08/30/2006 | EP1695979A2 Gapped 2' modified oligonucleotides |